Skip to content
Maui Sky – Lifestyle
Author:
Fractyl Health, Inc.
Fractyl Health Strengthens Revita Patent Portfolio as It Advances Toward FDA Submission and Potential Commercialization
October 30, 2026
Fractyl Health Announces Market Research Highlighting Substantial Patient Interest in a One-Time Procedural Approach to Post-GLP-1 Weight Maintenance
October 29, 2026
Fractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing Toward Planned FDA De Novo Submission in Post-GLP-1 Weight Maintenance
October 22, 2026
Fractyl Health’s Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 Discontinuation
October 18, 2026
Fractyl Health to Participate in Upcoming September Investor Conferences
September 9, 2026
Fractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita®, a Procedural Therapy for Post-GLP-1 Weight Maintenance
August 20, 2026
Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates
August 10, 2026
Fractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026
August 3, 2026
Fractyl Health to Participate in Upcoming Investor Events
July 22, 2026
Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation
July 15, 2026
1
2
Next Page
→